155 related articles for article (PubMed ID: 38743346)
1. Implications and interchangeability of meningioma biomarkers for clinical trials and clinical practice.
Raleigh DR; Chen WC; Gondi V; Rogers L; Mehta M
J Neurooncol; 2024 May; ():. PubMed ID: 38743346
[No Abstract] [Full Text] [Related]
2. Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications.
Dowlat HA; Kuhlmann MK; Khatami H; Ampudia-Blasco FJ
Diabetes Obes Metab; 2016 Aug; 18(8):737-46. PubMed ID: 27097592
[TBL] [Abstract][Full Text] [Related]
3. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group.
Huang RY; Bi WL; Weller M; Kaley T; Blakeley J; Dunn I; Galanis E; Preusser M; McDermott M; Rogers L; Raizer J; Schiff D; Soffietti R; Tonn JC; Vogelbaum M; Weber D; Reardon DA; Wen PY
Neuro Oncol; 2019 Jan; 21(1):26-36. PubMed ID: 30137421
[TBL] [Abstract][Full Text] [Related]
4. Phosphohistone H3: implications for clinical practice and risk assessment in meningioma.
Olar A
Neuro Oncol; 2015 May; 17(5):631-3. PubMed ID: 25813470
[No Abstract] [Full Text] [Related]
5. Equivalence assessment for interchangeability based on two-sided tests.
Dong X; Tsong Y
J Biopharm Stat; 2014; 24(6):1312-31. PubMed ID: 25032976
[TBL] [Abstract][Full Text] [Related]
6. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable.
Afzali A; Furtner D; Melsheimer R; Molloy PJ
Adv Ther; 2021 May; 38(5):2077-2093. PubMed ID: 33745111
[TBL] [Abstract][Full Text] [Related]
7. Interchangeability in Military Interprofessional Health Care Teams: Lessons Into Collective Self-healing and the Benefits Thereof.
Cristancho S; Field E; Bader-Larsen KS; Varpio L
Mil Med; 2021 Oct; 186(Suppl 3):16-22. PubMed ID: 34724051
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of somatostatin receptor positron emission tomography imaging biomarkers for characterization of meningioma among incidental central nervous system lesions.
Ensign SF; Agarwal M; Klanderman M; Badawy M; Halfdanarson TR; Johnson DR; Sonbol MB; Kendi AT
Nucl Med Commun; 2023 Jul; 44(7):663-670. PubMed ID: 37158225
[TBL] [Abstract][Full Text] [Related]
9. Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?
Alvarez DF; Wolbink G; Cronenberger C; Orazem J; Kay J
BioDrugs; 2020 Dec; 34(6):723-732. PubMed ID: 32990892
[TBL] [Abstract][Full Text] [Related]
10. Updated Systematic Review on the Role of Brain Invasion in Intracranial Meningiomas: What, When, Why?
Brunasso L; Bonosi L; Costanzo R; Buscemi F; Giammalva GR; Ferini G; Valenti V; Viola A; Umana GE; Gerardi RM; Sturiale CL; Albanese A; Iacopino DG; Maugeri R
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077700
[TBL] [Abstract][Full Text] [Related]
11. Ecological interchangeability: supporting team adaptive expertise in moments of disruption.
Cristancho S; Field E; Lingard L; Taylor T; Hibbert K; Thompson G; Hibbert W
Adv Health Sci Educ Theory Pract; 2022 Dec; 27(5):1361-1382. PubMed ID: 36357657
[TBL] [Abstract][Full Text] [Related]
12. INTERCHANGEABILITY OF VIRAL VACCINES FOR IMMUNIZATION.
Snegireva II; Darmostukova MA; Zatolochina KE; Kazakov AS; Alyautdin RN
Vopr Virusol; 2017 Oct; 62(5):197-203. PubMed ID: 36494950
[TBL] [Abstract][Full Text] [Related]
13. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
[TBL] [Abstract][Full Text] [Related]
14. Interchangeability of cardiac output measurements between non-invasive photoplethysmography and bolus thermodilution: A systematic review and individual patient data meta-analysis.
Fischer MO; Joosten A; Desebbe O; Boutros M; Debroczi S; Broch O; Malbrain MLNG; Ameloot K; Hofer CK; Bubenek-Turconi ŞI; Monnet X; Diouf M; Lorne E
Anaesth Crit Care Pain Med; 2020 Feb; 39(1):75-85. PubMed ID: 31170485
[TBL] [Abstract][Full Text] [Related]
15. The outcomes measured and reported in intracranial meningioma clinical trials: A systematic review.
Millward CP; Keshwara SM; Armstrong TS; Barrington H; Bell S; Brodbelt AR; Bulbeck H; Dirven L; Grundy PL; Islim AI; Javadpour M; Koszdin SD; Marson AG; McDermott MW; Meling TR; Oliver K; Plaha P; Preusser M; Santarius T; Srikandarajah N; Taphoorn MJB; Turner C; Watts C; Weller M; Williamson PR; Zadeh G; Zamanipoor Najafabadi AH; Jenkinson MD;
Neurooncol Adv; 2024; 6(1):vdae030. PubMed ID: 38596717
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation meningioma biomarkers: attributes and limitations.
Li Z; Gao Y; Zhang J; Han L; Zhao H
Front Mol Neurosci; 2023; 16():1182759. PubMed ID: 37492524
[TBL] [Abstract][Full Text] [Related]
17. Towards Molecular Classification of Meningioma: Evolving Treatment and Diagnostic Paradigms.
Proctor DT; Ramachandran S; Lama S; Sutherland GR
World Neurosurg; 2018 Nov; 119():366-373. PubMed ID: 30138732
[TBL] [Abstract][Full Text] [Related]
18. Statistical and regulatory considerations in assessments of interchangeability of biological drug products.
Tóthfalusi L; Endrényi L; Chow SC
Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S5-11. PubMed ID: 24832831
[TBL] [Abstract][Full Text] [Related]
19. Efficacy Endpoints in Phase II Clinical Trials for Meningioma: An Analysis of Recent Clinical Trials.
Watanabe S; Nonaka T; Maeda M; Sugii N; Hashimoto K; Takano S; Koyanagi T; Yamada M; Arakawa Y; Ishikawa E
Ther Innov Regul Sci; 2023 May; 57(3):603-610. PubMed ID: 36602756
[TBL] [Abstract][Full Text] [Related]
20. Equivalence tests for interchangeability based on two one-sided probabilities.
Dong X; Tsong Y; Shen M
J Biopharm Stat; 2014; 24(6):1332-48. PubMed ID: 25033074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
